Absci targets mid-2027 start for Phase 2 STORYLINE trial of ABS-201 in endometriosis pain

• Absci outlined a planned Phase 2 STORYLINE trial for ABS-201, an AI-designed antibody for endometriosis-associated pain.
• No Phase 2 results have been presented; trial initiation is targeted for mid-2027, following ongoing Phase 1 HEADLINE readouts.
• The study is designed to test whether ABS-201 can relieve endometriosis pain with a non-hormonal approach while maintaining acceptable safety.
• The global, placebo-controlled trial is expected to enroll about 150 patients across 10 or more countries.
• STORYLINE is planned as a dose-ranging study, with final dose selection dependent on Phase 1 safety and pharmacokinetic data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240800PRIMZONEFULLFEED9832965) on September 24, 2026, and is solely responsible for the information contained therein.